Pfizer (PFE) EBITDA Margin (2009 - 2026)

Pfizer has disclosed EBITDA Margin across 18 years of filings, most recently posting 286.83% for Q1 2026.

• In Q1 2026, EBITDA Margin rose 2760.0% year-over-year to 286.83%; the TTM figure through Mar 2026 stood at 72.46% (down 4104.0% YoY), while the FY2025 annual figure was 33.13%, up 47426.0% from the prior year.
• EBITDA Margin fell to 286.83% in Q1 2026, from 23.64% in the prior quarter.
• Over the last five years, EBITDA Margin for PFE reached as high as 47.01% in Q3 2022 and fell as low as 2483.26% in Q3 2024.
• The 5-year median for EBITDA Margin is 196.8% (2023), against an average of 341.58%.
• Annual changes were most pronounced in 2024 — EBITDA Margin tumbled 164612 bps — and 2025, when it surged 214196 bps.
• A 5-year view of EBITDA Margin shows it stood at 45.55% in 2022, then sank by 938 bps to 381.77% in 2023, then sank by 550 bps to 2483.26% in 2024, then jumped by 101 bps to 23.64% in 2025, then slumped by 1313 bps to 286.83% in 2026.
• According to Business Quant data, EBITDA Margin over the past three periods registered 286.83%, 23.64%, and 341.3% for Q1 2026, Q4 2025, and Q3 2025 respectively.